Herpes simplex virus type 1 (HSV-1) is a neurotropic doublestranded DNA virus that causes cold sores, keratitis, and rarely encephalitis in humans. Nonpathogenic HSV-1 gene transfer vectors have been generated by elimination of viral functions necessary for replication. The life cycle of the native virus includes replication in epithelial cells at the site of initial inoculation followed by retrograde axonal transport to the nuclei of sensory neurons innervating the area of cutaneous primary infection. In this review, we summarize the current understanding of the molecular basis for HSV cell entry, nuclear transport of the genome, virion egress following replication, and retrograde and anterograde axonal transport in neurons. We discuss how each of these properties has been exploited or modified to allow the generation of gene transfer vectors with particular utility for neurological applications. Recent advances in engineering virus entry have provided proof of principle that vector targeting is possible. Furthermore, significant and potentially therapeutic modifications to the pathological responses to various noxious insults have been demonstrated in models of peripheral nerve disease. These applications exploit the natural axonal transport mechanism of HSV, allowing transgene expression in the cell nucleus within the inaccessible trigeminal ganglion or dorsal root ganglion, following the noninvasive procedure of subcutaneous vector inoculation. These findings demonstrate the importance of understanding basic virology in the design of vector systems and the powerful approach of exploiting favorable properties of the parent virus in the generation of gene transfer vectors. Gene Therapy (2005) 12, 891-901.
Introduction
Herpes simplex virus type 1 (HSV-1) is a promising vehicle for gene transfer applications. HSV-1 is a large double-stranded DNA virus that can accommodate large or multiple transgene cassettes and replication-defective viruses can be constructed for gene delivery without vector-associated toxicity. HSV-1 has a broad host range and does not require cell division for infection and gene expression. Furthermore, HSV-1 can persist in a variety of cell types and express transgenes long term by exploiting the viral mechanisms involved in latent neuronal infection.
The mature HSV-1 virion consists, from the surface inward, of a trilaminar lipid envelope, an amorphous proteinaceous region termed the tegument, an icosadeltahedral protein capsid, and a double-stranded DNA genome ( Figure 1a) . The virus particle is composed of at least 34 proteins, 1,2 many of which are post-translationally modified by cellular and viral enzymes. The lipid envelope contains at least 11 virus-encoded glycoproteins that participate in many aspects of the virus life cycle including attachment and entry, [3] [4] [5] cell-to-cell spread, 6 and immune evasion. [7] [8] [9] Proteins residing in the underlying tegument are responsible for initiating gene expression from the viral genome, 10, 11 shutting off host cell protein synthesis, 12, 13 and assist in virion maturation and egress. [14] [15] [16] [17] [18] The virion proteins VP5, VP19c, VP23, and VP26 [19] [20] [21] [22] form the icosadeltahedral capsid that encases the double-stranded DNA genome. The 152 kb viral genome encodes 84 genes (Figure 1b) , and consists of a unique long (U L ) and a unique short (U S ) segment (Figure 1b ) each flanked by repeat sequences (ab, b 0 a 0 , a 0 c 0 ca) [23] [24] [25] [26] [27] that can invert relative to one another.
In vivo, the life cycle of HSV is complex and characterized by a series of interactions between virus, neuronal and non-neuronal host cells, and the immune system. Lytic infection at the epithelial or mucosal surface allows progeny virions to enter the axons of sensory neurons innervating the affected area. Viral components, including the genome, are retrogradely transported to the neuronal nuclei in either the dorsal root ganglia (DRG) or trigeminal ganglion (TG). In the unique microenvironment provided by the nerve cell nucleus, the virus may enter a latent state, and it may remain in this state for the lifetime of the host. However, certain provoking factors, such as intercurrent illness or immunosuppression, can cause reactivation. Upon reactivation, progeny virions are produced and anterogradely transported back to nerve terminals where they are assembled and released giving rise to a recurrent infection at or near the site of initial inoculation. The dynamics of this fascinating journey from one topologi-cal location and cell type to another will form the focus of this review. In the following paragraphs, we discuss the mechanisms whereby HSV-1 delivers its contents to epithelial cells, how the genome and tegument proteins find their way into the cell nucleus, the means by which virions are assembled and released, and importantly, our current understanding of the interactions between viral components and the neural cytoskeleton that mediate transport of the virus along axons. Each of these mechanisms can be exploited in the design of gene therapy vectors, particularly with regard to neurological applications. Consequently, the extensive literature on these basic processes has informed the development of experimental and potentially therapeutic reagents for applications as diverse as malignant glioma, chronic pain, peripheral neuropathy, and neurodegeneration.
Virus attachment and entry
Entry of HSV-1 into the cell occurs through fusion of the viral envelope with the plasma membrane 3, 4, 28 or an internal endosomal membrane. 29, 30 Entry at the plasma membrane is pH independent, while entry via an endosomal compartment is pH dependent. While HSV-1 has been shown to enter most cells via the pHindependent, transplasmalemmal route, it has been hypothesized that the route of entry may vary depending upon the cell type. 30 The following comments are mainly applicable to the pH-independent, transplasmalemmal route of entry, which has been extensively studied.
Of the 11 glycoproteins expressed on the virus envelope, only four are absolutely required for infection in vitro. gB, gD, gH, and gL are essential for viral infection, [31] [32] [33] [34] while gC, gE, gG, gI, gJ, gK, and gM are dispensable for infection in vitro. [2] [3] [4] Some glycoproteins form functional homo-oligomers (eg gB), [35] [36] [37] [38] [39] [40] while others form functional hetero-oligomers (gH/gL, gI/ gE). 33 ,41,42 HSV-1 attachment and entry is a multistep process ( Figure 2 ). Binding to cell surface glycosaminoglycans (GAGs), primarily heparan sulfate (HS), [43] [44] [45] [46] [47] [48] [49] is mediated by exposed domains of glycoproteins C 50 and B. 51, 52 The HS-binding domains were mapped to regions within gC, 49, 53 including amino acids 136-152, and a short stretch of lysine residues encompassing amino acids 68-76 within gB. 54, 55 Deletion of gC, and the HSbinding domain of gB, in a single mutant virus impairs binding (ie slower kinetics) to an extent similar to the reduced binding of wild-type virus on HS-deficient cells. 44, 54 However, virus adsorption is not completely eliminated in either situation, indicating that other receptors are involved. Since GAGs are ubiquitous, it is thought that the initial binding of virus to these cell (Figure 2b ). Work by several labs has identified gD-cognate receptors utilized for both virus attachment and penetration. The first herpesvirus entry mediator (HVEM or HveA), a member of the TNFa/NGF receptor family, was identified by screening a cDNA expression library in HSV-1-resistant CHO cells for clones that enabled virus infection. 56 Domains of gD that contribute to HveA binding have been identified in virus infection inhibition studies using monoclonal antibodies that recognize residues 11-19 and 222-252. 57 Consistent with these data, incubation of soluble gD with the host cell prior to infection can block infection by wild-type virus, but mutants with single amino-acid substitutions in the external domain at residues 25 (L25P) or 27 (Q27P, Rid1) can circumvent this blocking activity of gD, 58 suggesting that these residues are crucial for binding to HveA. Deletion of residues 6-24 as well as a series of point mutations primarily within the N-terminus of gD prevents binding and entry through HveA 59 (Bai et al, unpublished). These results are in agreement with crystal structure data pinpointing the binding site for HveA and demonstrate that HveA binding to the N-terminus of gD results in a conformational change that may be responsible for inducing virus envelope fusion with the cell surface. 59, 60 Together, these studies suggest that HveA is recognized by a folded part of gD that can be affected by mutations spanning a substantial portion of the molecule.
A number of other gD entry mediators have been identified, including HveB (nectin-2), 61 3-O-sulfated HS, 62 and HveC (nectin-1). 63 HveC is ubiquitously expressed on most cells, including epithelial and neuronal cells, [63] [64] [65] [66] and is generally considered to be the main HSV-1 entry receptor. HveC is a member of the immunoglobulin superfamily and has no structural relationship to HveA. 63, 67 A type I integral membrane protein, HveC, contains a variable (V) domain and two constant (C) domains, but attachment of HSV-1 via gD to only the V domain is necessary and sufficient to initiate fusion of the virus with the cell. 68 Two potentially related but separate HveC binding sites appear to coexist within gD. Certain substitutions within the amino-terminus of gD that affect binding and entry through HveA also eliminate binding/entry via HveC (Bai et al, unpublished data). Additionally, residues 216-234 have been implicated in the HveC:gD interaction, in as much as monoclonal antibodies specific for an epitope in this region interfere with gD recognition of HveC but not HveA. 67 Recently, the first mutants of gD that inactivate binding to HveC while preserving the recognition of HveA were identified 69 (Shah et al, unpublished). The consequence of the sequential attachment steps in infection is fusion of the virus envelope with the cell surface membrane (Figure 2c and d) and subsequent entry 3, 4 of the nucleocapsid and tegument proteins into the cytoplasm of the cell (Figure 2e) . A role for gD in virus penetration is supported by evidence that attached virus can be neutralized by anti-gD antibody and virus mutants deleted for gD attach to cells but do not penetrate. 34, 70, 71 Mutants deleted for gH/gL 72, 73 or gB 74, 75 are also blocked in virus penetration, but are not defective in attachment. Furthermore, gB, gD, and gH/ gL are all required for cell-to-cell fusion. 76 Fuller and Lee 43 proposed that entry involves a cascade of events in which gD initiates the fusion process. According to their hypothesis, a fusion bridge is most likely formed by the action of gB followed by extension of the bridge and virus release requiring the activities of gH/gL. In addition to external entry, HSV-1 is also capable of infecting neighboring cells by moving transcellularly across cell membranes. This process, referred to as cellto-cell or lateral spread, appears distinguishable from infection by extracellular virus. Thus, lateral spread occurs in the presence of neutralizing antibodies and is reduced by deletion of certain accessory envelope glycoproteins (eg gI/gE), which are not necessary for initial infection. 6, 77 Upon entry into the cell, HSV-1 capsids are propelled toward the minus end of microtubules 78 through an interaction of the HSV-1 tegument protein UL34 with cellular dynein. [79] [80] [81] The capsid docks at nuclear pore complexes (NPC) and the viral genome is deposited into the nucleus. 82 Following nuclear entry, the tegument protein VP16, in coordination with the cellular proteins Oct-1 and HCF-111, 83 initiates transcription of the five viral immediate-early (IE) genes, ICP0, ICP4, ICP22, ICP27, and ICP47, by binding to specific promoter elements within these genes. 28 The expression of the IE genes in turn transactivates the early genes that mainly encode enzymes involved in viral DNA synthesis and replication. The late genes, which encode structural proteins, are transactivated by the IE proteins after the onset of DNA replication. [84] [85] [86] The assembly of HSV particles occurs in the nucleus where capsids attach to modified patches of the inner lamella of the nuclear membrane. Budding of DNAcontaining capsids occurs at these sites, where enveloped particles are formed. HSV-1 particles then lose their envelope after budding through the outer leaflet of the nuclear membrane. Capsids are then re-enveloped, acquire their glycoproteins [87] [88] [89] [90] by budding into vesicles within the transgolgi network, and are released from the cell. 14, [91] [92] [93] [94] [95] Retrograde transport to the neuronal cell nucleus HSV-1 initially infects epithelial cells within the skin or mucosae (Figure 3a) , where the virus undergoes a lytic replication cycle. The resulting progeny virus is released onto the skin surface, allowing transmission to another host, and also into the subcutaneous region, allowing virus to enter sensory neurons that innervate the infected area (Figure 3b ). Within neurons, HSV-1 nucleocapsid and tegument proteins travel in a retrograde manner to the neuronal cell body where the viral genome is released into the nucleus. [96] [97] [98] The transport of alphaherpesvirus nucleocapsids along axons has been estimated to occur at rates of 0.5-3.5 mm/s, 99 suggesting that transport is an active process. While the exact mechanism of HSV transport along axons has yet to be elucidated, recent studies have identified viral and host cell components that contribute to this process. Bearer et al 100 utilized the giant axon of the squid, Loligo pealei,
as a model system to study HSV axonal transport. In this system, the tegument and capsid of HSV, but not the envelope, were able to recruit efficiently the retrograde transport machinery of the squid for axonal transport. Consistent with findings in the squid model, Lavail et al 101 also showed that gD from the viral envelope and the capsid component VP5 entered axons independently of one another in a temporal manner in a mouse model.
The ability of microtubule-inhibiting drugs such as nocadozole, colchisine, and vinblastine to inhibit HSV axonal transport provided evidence that HSV components utilize the host cell microtubule network for this process. 102, 103 The rapid movement of HSV in a retrograde manner would require association with a minusend-directed motor molecule to propel the nucleocapsids toward the minus end of the microtubule network. 
HSV vector trafficking
AR Frampton et al specifically interacts with the neuronal isoform of the intermediate chain of cytoplasmic dynein, one of the largest motor proteins involved in retrograde transport. 104 Dohner et al 79 showed by immunofluorescence analyses that HSV-1 capsids colocalize with dynein as well as its cofactor dynactin. In addition, viral nucleocapsid transport was significantly decreased after disruption of the dynein-dynactin complex. Together, these data provide evidence implicating dynein as the minusend motor molecule that mediates retrograde transport of HSV components in neurons. Upon reaching the nucleus, the nucleocapsid docks at the NPC and viral DNA is inserted into the nucleoplasm.
Reactivation from latency and anterograde transport to the nerve terminal
In the neuronal cell nucleus, HSV-1 persists in a latent state as a stable episomal element 105 ( Figure 3c ). All viral genes are shut off during the latent phase, except a small set of latency-associated transcripts (LATs) that are transcribed from the repeat region flanking the U L segment of the genome. [106] [107] [108] [109] [110] While the role of these LATs is not well understood, some data point to their involvement in the establishment and maintenance of the latent state, or in reactivation from latency.
111-115 HSV-1 can be reactivated from the latent state (Figure 3d) by intercurrent illness or immunosuppression and, through viral replication in the neuron and anterograde transport of viral components to the site of initial epithelial infection, cause a recurrent mucocutaneous infection. Once reactivated, the HSV-1 IE genes are expressed and the lytic replication cycle ensues within the neuron. Viral genomes are packaged into assembled capsids within the nucleus and the virus buds from the inner and outer nuclear membranes. The virus is transported back to the initial site of infection by traveling in an anterograde manner along axons. 116, 117 Recent data indicates that HSV-1 anterograde movement along the axons occurs rapidly 118 and is dependent upon plus-end microtubule motors that move capsids toward the axon terminal. 78, 103, 119 Investigation into HSV components that may contribute to axonal transport led to the finding that the viral RNA-binding protein US11 120 interacts with the ubiquitous kinesin heavy chain, which functions in microtubule-dependent fast axonal transport of organelles. The binding interaction was mapped to amino acids 867-894 of US11 and the heptad repeat cargobinding domain of kinesin. Satpute-Krishnan et al also showed that amyloid precursor protein, a putative kinesin receptor, 121, 122 associates with viral particles during anterograde transport. Similar to retrograde movement, data are accumulating that HSV nucleocapsids and tegument travel separately from envelope components in anterograde transport. For example, the ability of the golgi transport inhibitor brefeldin A to block specifically transport of glycoproteins, but not nucleocapsids, suggests that these viral components travel independently along axons similar to retrograde transport. 116 Collectively, these data show that HSV movement along axons is an active process requiring the coordinated activity of both viral and host cell factors. Further work utilizing HSV recombinants deleted for microtubule motor-binding proteins will further define the specific interactions between host and viral components critical for the rapid movement of HSV along axons. After reaching the axon terminal, HSV-1 exits the terminal and infects neighboring cells initiating a recrudescent infection (Figure 3e ) at or near the initial site of infection.
Exploiting the natural biology of HSV trafficking to generate effective neurological gene transfer vectors HSV-1 can be engineered to produce an effective gene transfer vector for experimental and potentially therapeutic uses in the nervous system. The generation of replication-defective genomic HSV vectors with minimal toxicity is beyond the scope of this review, as is the use of the latency promoter complex to achieve long-term transgene expression in neurons. However, various aspects of the basic biology of viral trafficking have been exploited to expand the utility of HSV vectors as therapeutic agents for diseases of the PNS and CNS.
Native cell entry properties
Owing to its natural tropism for neuronal cells, HSV-1 can deliver transgenes to the nervous system without the need to alter the virus surface components. In the peripheral nervous system, the HSV-1 receptor HveC is abundantly expressed on sensory neurons, 64 and this receptor is the main mediator of viral entry into these cells. 66 The expression of the natural HSV receptor obviates the need to alter the HSV-1 virion surface in order to target specifically this set of neurons. Although peripheral transduction of motor neurons has been reported using HSV vectors with unmodified surface components, 123, 124 this process is relatively inefficient due to the low levels of HSV receptors on motor neuron terminals. Specific peripheral targeting of motor neurons may require alteration of one or more of the viral glycoproteins, although transduction of motor neurons within the spinal cord is relatively more efficient as the viral entry receptors are expressed at higher levels in the motor neuronal somata. Since HveC is abundantly expressed in most CNS neurons, the transduction of neuronal populations at specific topological locations can be achieved by direct vector inoculation.
Retargeting HSV-1 to specific cell types
In some instances, cells are refractory to HSV infection due to low or undetectable expression of the natural HSV receptors. An example is provided by the peripheral terminals of motor neurons. In other instances, the widely distributed expression of the native cell surface receptors is a distinct disadvantage, for example, when transduction of a rare cell type is desired in the context of abundant surrounding cells that provide a sink for vector particles, or when transgene expression is required in a specific cellular subpopulation. In these instances, it will be necessary to redirect HSV binding and entry by generating viral vectors that carry engineered ligands that recognize specific cell surface receptors. Successful development of this technology depends on both the identification of appropriate cell-specific surface receptor(s) and the ability to modify viral surface proteins for HSV vector trafficking AR Frampton et al recognition of these novel receptors without compromising infectivity.
Two criteria must be met to successfully retarget HSV-1 to specific cell types. First, the natural receptor-ligand interactions of the virus must be ablated. Second, the virus must be redirected to alternate receptors either through manipulation of the virus surface or via adaptor molecules. Regions within gC and gB, which contribute to over 80% of HS binding have been mapped and deletion of these regions from HSV-1 resulted in a virus that has a significant defect in binding to cells. 54 In addition, domains within gD have been defined that specifically interact with either HveA or HveC (Shah et al, unpublished data). 57, 60, [67] [68] [69] 125, 126 This understanding of the basic biology of HSV-1 binding and entry has enabled the development of HSV vectors designed to target specifically distinct cell populations.
The first successfully redirected HSV vector was developed by Laquerre et al. 55 HSV-1 was engineered to express the EPO protein on the viral surface through insertion of the Epo ligand into the HS binding region of gC (Figure 4a) . Viruses expressing the Epo-gC fusion protein exhibited a significant reduction in binding to cell surface GAGs and specifically bound to the EPO receptor (EPO-R) present on cells that also lack HveA/C. Moreover, the ability of virally expressed Epo to stimulate the EPO-R indicated that Epo, expressed as a fusion protein with gC, was biologically active. This HSV-1 vector indicated for the first time that HSV-1 tropism could be altered via insertion of a ligand into a viral glycoprotein. However, this first-generation vector still retained the ability to bind to the natural HSV-1 receptors, HveA and HveC.
Zhou et al 127 retargeted an HSV-1 recombinant to IL13Ra2-expressing cells (Figure 4b ) through expression of IL-13 on the viral surface. Binding to GAGs was significantly reduced through elimination of the HSbinding domains of gB and gC, and IL-13 was inserted into the N-terminus of both gC and gD, effectively destroying the ability of HSV-1 to bind to the HveA receptor, but retaining the ability to still interact with HveC. This HSV recombinant was shown to efficiently enter and replicate in cells that express the IL-13Ra2 receptor. These results showed that, in addition to elimination of HS binding, the HveA-binding domain could be altered without affecting virus entry. However, this recombinant was not impaired for entry on cells bearing the HveC receptor.
In a similar manner, HSV-1 was also engineered to bind to hepatocytes (Figure 4c ) through the expression of hepatitis B virus pre-S1 and a pre-S1 peptide. 128 The expression of these molecules from an HSV-1 recombinant increased entry into hepatocytes compared to the parental virus that was impaired in binding to GAGs. While this recombinant displayed increased entry kinetics on hepatocytes, wild-type HSV-1 entry was even more efficient than the recombinant, indicating that the preferred mode of entry in these cells was mediated by an interaction of gD with one or more of the natural receptors present on hepatocytes. Grandi et al 129 replaced the HS-binding domain of gC with a His-tag sequence (Figure 4d ) and showed that this vector exhibited a fourfold increase in binding to 293T cells expressing a pseudo-His-tag receptor. Collectively, these data showed that HSV-1 vectors that bind to cells expressing an alternate receptor can be generated without disrupting the fusogenic properties of viral surface components.
Exploiting axonal transport for delivery of therapeutic agents
Exploitation of the inherent neurotropism of the parent virus has led to the development of HSV gene delivery vectors with particular utility in neurological applications. Replication-defective genomic vectors are constructed by deletion of essential IE genes from the viral genome, preventing progression of the viral gene expression cascade in vivo. Complementation of these genes in trans in cell lines enables virus replication and The peripheral sensory nervous system is the natural host tissue for wild-type viral latency and is a natural setting in which to attempt recapitulation of viral transport mechanisms using replication-defective vectors. Since viral receptors are abundantly expressed on the peripheral terminals of sensory neurons, subcutaneous inoculation would be expected to allow neural transduction.
Experimental data confirm that peripheral inoculation enables replication-defective vectors to utilize the same retrograde transport system used by wild-type virus to reach the sensory ganglia. 124, [130] [131] [132] [133] In some circumstances, replication-defective vector apparently effects less efficient neuronal transduction than does replication-competent virus, 133 although this is likely a manifestation of the initial round of lytic replication in epithelia, which amplifies the virus dose delivered to nerves, because an elevated dose of replication-deficient vector allows efficient nerve transduction via peripheral cutaneous infection. 130, 133 This important feature of HSV vectors has raised the realistic possibility of therapeutically modifying the function of sensory nerves in patients by gene transfer. Peripheral inoculation is a relatively noninvasive procedure involving a subcutaneous injection to deliver vector via axonal transport to the neuronal cell body in the inaccessible DRGs. Two broad applications that utilize these observations have been studied. First, the neurochemical phenotype of sensory cells has been modified by gene delivery in models of pain. Second, in models of peripheral neuropathy, molecules that enhance the viability of neurons under conditions of metabolic stress have been expressed in neurons by HSV-mediated gene transfer.
Chronic pain is a major problem affecting millions of people with enormous associated health-care costs. 134 The capacity of HSV vectors to introduce exogenous genetic material into sensory neurons has allowed the development of gene therapy strategies to treat chronic pain. Proof of concept that peripheral HSV inoculation could modify the neurochemical properties of sensory neurons and consequently the behavioral response to painful stimuli was initially shown in a mouse model of hyperalgesia. A vector was engineered to express the opioid peptide precursor, human preproenkephalin, 135 the post-translational processing of which yields enkephalin, a ligand that binds opiate receptors in the spinal cord involved in the modulation of pain transmission in the dorsal horn. After inoculation of the skin of mouse footpads, human proenkephalin was detected in primary sensory axons in the dorsal roots and substantia gelatinosa of the dorsal horn. Animals pretreated with the proenkephalin vector were resistant to hyperalgesic sensitization of myelinated and unmyelinated nociceptors. The effect of the vector lasted 4-6 weeks and was reversed by the opioid receptor antagonist naloxone. These initial studies have been extended in a variety of animal models, including a formalin model of chronic pain, 136 and models of bone metastasis pain, 137 bladder pain, 138 and spinal cord injury pain, 139 using a variety of different analgesic transgenes including opioid receptor ligands 136 and glutamic acid decarboxylase. 140 Furthermore, in one paradigm, the waning analgesic effect associated with declining transgene expression several weeks after initial inoculation was re-established following repeat inoculation, indicating that tolerance to the transgene product did not develop. 136 In view of these promising results in preclinical studies, it is possible that HSV gene therapy clinical trials for chronic pain will commence in the foreseeable future.
HSV vectors have also been used to deliver trophic agents to sensory neurons in order to protect them from metabolic insults that result in various types of peripheral neuropathy. A HSV vector expressing the betasubunit of NGF was inoculated into the wall of the bladder in mice; 3 days postinfection, NGF was detected in both the bladder wall and the visceral sensory neurons of the DRG, indicating that the autonomic sensory fibers had been transduced and that the vector had been transported to the neuronal cell nucleus by retrograde axonal transport. 141 This observation may be exploited for the development of therapies for the autonomic neuropathy associated with diabetes. 142 In other studies, somatosensory neurons of rats were transduced by peripheral inoculation with a vector expressing neurotrophin-3 (NT-3). 143 Pretreatment with the NT-3-expressing vector significantly protected sensory axons from the toxic effects of pyridoxine overdose, demonstrated by behavioral, morphological, and electrophysiological analyses. Furthermore, administration of NGF-and NT-3-expressing HSV vectors protected animals from cisplatin-induced neuropathy. 144 Overall these studies indicate that HSV vectors may find utility in the treatment of peripheral neuropathy with the exploitation of axonal transport mechanisms by HSV as a key component in these applications.
In the CNS, HSV axonal transport may be exploited to achieve the transduction of inaccessible sites via inoculation of relatively more accessible sites. A major component of the pathology in Parkinson's disease occurs within the substantia nigra (SNc) pars compacta, which is located at the rostral end of the midbrain and difficult to access surgically for stereotactic inoculation of vector. However, the major projection from the SNc to the striatum allows vector inoculation into the relatively more accessible caudate or putamen, with accompanying retrograde transport to the cell bodies of the SNc, where neuroprotective genes might be expressed to alleviate progression of the pathology. The development of vectors that are deleted for multiple IE genes has allowed the successful use of this system in the CNS with little observed toxicity and vectors for applications in neurodegenerative disease are currently under development. [145] [146] [147] In one study, reporter gene expression at CNS sites remote from the site of initial inoculation was observed. Inoculation at the striatum, spinal cord, and superior colliculus was accompanied by expression of transgene at the SNc, retinal ganglion cells, DRG, brainstem, hind-, and mid-brain. 147 These results demon-HSV vector trafficking AR Frampton et al strated that an HSV vector could be efficiently delivered to, and utilize the retrograde transport machinery of, CNS neurons without a decrease in transgene expression, and suggest that HSV gene therapy may be extended to applications involving CNS disorders.
Conclusions
The basic biology of HSV is being slowly unraveled by a large series of painstaking studies carried out by many groups. These studies have revealed a complex set of interactions between HSV and host, which underlie the mechanisms responsible for the journey of the virus from initial epithelial attachment, entry and lytic infection, to latent infection in cells of the trigeminal and DRG, and subsequent reactivation. Each of these properties has been exploited in different ways for the generation of HSV vectors with therapeutic applications as diverse as malignant glioma and peripheral neuropathy. It is anticipated that further vector development will exploit other native properties of the virus, allowing efficient gene delivery and distribution, while deleting pathogenic functions.
